Multicenter, randomized, double-blinded, placebo-controlled, phase 3 clinical efficacy study evaluating nitric oxide nasal spray (NONS) as a prevention treatment for individuals at risk of exposure to COVID-19 infection - Trial SLCTR_2021_034
Access comprehensive clinical trial information for SLCTR_2021_034 through Pure Global AI's free database. This Phase 3 trial is sponsored by SaNOtize Research and Development Corporation and is currently Recruiting. The study focuses on COVID-19.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
SLCTR_2021_034
Phase 3
Recruiting
Trial Details
Sri Lanka Clinical Trials Registry • SLCTR_2021_034
Multicenter, randomized, double-blinded, placebo-controlled, phase 3 clinical efficacy study evaluating nitric oxide nasal spray (NONS) as a prevention treatment for individuals at risk of exposure to COVID-19 infection
Multicenter, randomized, double-blinded, placebo-controlled, phase 3 clinical efficacy study evaluating nitric oxide nasal spray (NONS) as prevention for treatment of individuals at risk of exposure to COVID-19 infection
Study Focus
Interventional
Sponsor & Location
SaNOtize Research and Development Corporation
Sri Lanka
Timeline & Enrollment
Phase 3
Jan 13, 2022
N/A
ICD-10 Classifications
COVID-19, virus identified
COVID-19, virus not identified
Coronavirus infection, unspecified site
Viral infection, unspecified
Rift Valley fever
Data Source
Sri Lanka Clinical Trials Registry
SLCTR_2021_034
Non-Device Trial